At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Plant Steroldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients Participating in a Cardiovascular Disease Prevention Program
In Brief
A Phase 4 clinical trial evaluating Plant Sterol for Cardiovascular Risk Factor. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The purpose of this study is to measure the incremental effectiveness of a twice daily plant sterol supplement in a population of South Asian patients who have low-to-moderate cardiovascular disease (CVD) risk.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Risk Factor
CountriesUnited States
CollaboratorsPiper Biosciences, Inc.
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartJan 2020
Primary CompletionMar 2021
TodayJul 2026
First PostedJul 23, 2019
Enrollment StartJan 6, 2020
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.9 years ago
Interventions
Plant Steroldrug
Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.